Status:
COMPLETED
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
Lead Sponsor:
Pfizer
Conditions:
Epilepsy, Partial
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
Eligibility Criteria
Inclusion
- Must have met the inclusion criteria for preceding double-blind study.
- Have received double-blind study medication and wish to receive open-label pregabalin.
Exclusion
- Pregnant or considering becoming pregnant.
- Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.
Key Trial Info
Start Date :
November 1 1997
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00141414
Start Date
November 1 1997
End Date
October 1 2005
Last Update
January 1 2007
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
2
Pfizer Investigational Site
Los Angeles, California, United States, 90033
3
Pfizer Investigational Site
Stanford, California, United States, 94305
4
Pfizer Investigational Site
Miami, Florida, United States, 33136